Economic evaluation of XXXX for @entity386 .

@entity1 @entity245 @entity5834 @entity27708 @entity386
OBJECTIVE: To determine the cost-effectiveness of treatment with @entity5834 compared with placebo for @entity386 in @entity1 with birth weights less than 1250 g, from birth through 18 to 21 months' corrected age. METHODS: We undertook a retrospective economic evaluation of the cost per survivor without @entity245 by using individual- @entity1 data from the @entity5834 for @entity386 clinical trial (N = 1869). We included direct medical costs either to the insurance payer or the hospital but excluded costs to parents and society, such as lost productivity. We used a price of  0.21/mg of generic @entity27708 for our base-case analysis. All costs were expressed in 2008 Canadian dollars and discounted at 3%. The time horizon for this analysis extended through 18 to 21 months' corrected age to match the clinical trial. RESULTS: The mean cost per @entity1 was  124 466 in the @entity5834 group and  133 505 in the placebo group (difference:  9039 [-14 749 to -3375]; adjusted P = .014). Cost-effectiveness analysis showed @entity5834 to be a dominant or "win-win" therapy: in >99% of 1000 bootstrap replications of the analysis, @entity5834 -treated @entity1 had simultaneously better outcomes and lower mean costs. These results were robust to a 1000% increase in the individual resource items, including the price of @entity27708 . CONCLUSIONS: In comparison with placebo, @entity5834 therapy for @entity386 in @entity1 weighing less than 1250 g is economically appealing for @entity1 up to 18 to 21 months' corrected age.
